A21Defining CTL immunotherapy candidates against replication-competent and defective HIVOn-demand oral abstract sessionImmunotherapy: Vaccines and antibodies
A21The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaquesOn-demand oral abstract sessionImmunotherapy: Vaccines and antibodies
A20GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell cultureOn-demand oral abstract sessionEliminating and silencing latency
A20Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremiaOral abstract session with live Q&AEliminating and silencing latency
A20XPB degradation by Spironolactone prevents HIV-1 reactivation from latencyE-posterEliminating and silencing latency
A20Dasatinib inhibits provirus reactivation in patients co-infected with HIV and HCVE-posterEliminating and silencing latency
A2The frequency of HLA-l alleles could influence the level of post-transmission readaptation of HIV-1E-posterViral fitness, persistence and resistance
A2Premutations could facilitate CTL escape in gag epitopes during early HIV-1 infectionE-posterViral fitness, persistence and resistance
A2Low-level HIV-1 viral load predicts virologic failure in antiretroviral experienced individuals in BotswanaE-posterViral fitness, persistence and resistance
A2High resistance mutation to cART in HIV-1 exposed infected children and recent emergence of CRF02_AG variant in Bouar, a rural environment of Central African RepublicE-posterViral fitness, persistence and resistance
831 - 840 of 870 items